Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.

Franzetti GA, Laud-Duval K, Bellanger D, Stern MH, Sastre-Garau X, Delattre O.

Oncogene. 2013 Aug 15;32(33):3915-21.

PMID:
22986530
2.

The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.

Vural C, Uluoğlu O, Akyürek N, Oğuz A, Karadeniz C.

Pathol Oncol Res. 2011 Sep;17(3):619-25. doi: 10.1007/s12253-010-9358-3.

PMID:
21267687
3.

Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.

Niedan S, Kauer M, Aryee DN, Kofler R, Schwentner R, Meier A, Pötschger U, Kontny U, Kovar H.

Oncogene. 2014 Jul 24;33(30):3927-38. doi: 10.1038/onc.2013.361.

4.

A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.

McKinsey EL, Parrish JK, Irwin AE, Niemeyer BF, Kern HB, Birks DK, Jedlicka P.

Oncogene. 2011 Dec 8;30(49):4910-20. doi: 10.1038/onc.2011.197.

5.

Characterization of human mesenchymal stem cells from ewing sarcoma patients. Pathogenetic implications.

Amaral AT, Manara MC, Berghuis D, Ordóñez JL, Biscuola M, Lopez-García MA, Osuna D, Lucarelli E, Alviano F, Lankester A, Scotlandi K, de Álava E.

PLoS One. 2014 Feb 3;9(2):e85814. doi: 10.1371/journal.pone.0085814. Erratum in: PLoS One.2014;9(4):e94455.

6.

Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis.

Stoll G, Surdez D, Tirode F, Laud K, Barillot E, Zinovyev A, Delattre O.

Nucleic Acids Res. 2013 Oct;41(19):8853-71. doi: 10.1093/nar/gkt678.

7.

Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.

Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, Currier DG, Davis S, Khanna C, Khan J, McMahon JB, Helman LJ.

J Natl Cancer Inst. 2011 Jun 22;103(12):962-78. doi: 10.1093/jnci/djr156.

8.

EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.

Robin TP, Smith A, McKinsey E, Reaves L, Jedlicka P, Ford HL.

Mol Cancer Res. 2012 Aug;10(8):1098-108. doi: 10.1158/1541-7786.MCR-12-0086.

9.

Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors.

Li Y, Li X, Fan G, Fukushi J, Matsumoto Y, Iwamoto Y, Zhu Y.

Cancer Lett. 2012 Jul 1;320(1):14-22. doi: 10.1016/j.canlet.2012.01.018.

PMID:
22266186
10.

Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.

Jully B, Vijayalakshmi R, Gopal G, Sabitha K, Rajkumar T.

BMC Cancer. 2012 Nov 12;12:513. doi: 10.1186/1471-2407-12-513.

11.

FOXM1 is an oncogenic mediator in Ewing Sarcoma.

Christensen L, Joo J, Lee S, Wai D, Triche TJ, May WA.

PLoS One. 2013;8(1):e54556. doi: 10.1371/journal.pone.0054556.

12.

PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.

Giorgi C, Boro A, Rechfeld F, Lopez-Garcia LA, Gierisch ME, Schäfer BW, Niggli FK.

Oncotarget. 2015 Oct 6;6(30):28895-910. doi: 10.18632/oncotarget.5000.

13.

The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors.

Mendiola M, Carrillo J, García E, Lalli E, Hernández T, de Alava E, Tirode F, Delattre O, García-Miguel P, López-Barea F, Pestaña A, Alonso J.

Int J Cancer. 2006 Mar 15;118(6):1381-9.

14.

SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.

Tang SW, Bilke S, Cao L, Murai J, Sousa FG, Yamade M, Rajapakse V, Varma S, Helman LJ, Khan J, Meltzer PS, Pommier Y.

Clin Cancer Res. 2015 Sep 15;21(18):4184-93. doi: 10.1158/1078-0432.CCR-14-2112.

15.

Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis.

Marques Howarth M, Simpson D, Ngok SP, Nieves B, Chen R, Siprashvili Z, Vaka D, Breese MR, Crompton BD, Alexe G, Hawkins DS, Jacobson D, Brunner AL, West R, Mora J, Stegmaier K, Khavari P, Sweet-Cordero EA.

J Clin Invest. 2014 Dec;124(12):5275-90. doi: 10.1172/JCI72124.

16.

Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma.

Ban J, Jug G, Mestdagh P, Schwentner R, Kauer M, Aryee DN, Schaefer KL, Nakatani F, Scotlandi K, Reiter M, Strunk D, Speleman F, Vandesompele J, Kovar H.

Oncogene. 2011 May 5;30(18):2173-80. doi: 10.1038/onc.2010.581.

17.

EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology.

Zhou Z, Yu L, Kleinerman ES.

Cancer. 2014 Feb 15;120(4):579-88. doi: 10.1002/cncr.28555.

18.

Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.

Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, Helman LJ.

Clin Cancer Res. 2014 Mar 1;20(5):1190-203. doi: 10.1158/1078-0432.CCR-13-0901.

19.

Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.

Grohar PJ, Kim S, Rangel Rivera GO, Sen N, Haddock S, Harlow ML, Maloney NK, Zhu J, O'Neill M, Jones TL, Huppi K, Grandin M, Gehlhaus K, Klumpp-Thomas CA, Buehler E, Helman LJ, Martin SE, Caplen NJ.

Cell Rep. 2016 Jan 26;14(3):598-610. doi: 10.1016/j.celrep.2015.12.063.

20.

Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro.

Aryee DN, Niedan S, Kauer M, Schwentner R, Bennani-Baiti IM, Ban J, Muehlbacher K, Kreppel M, Walker RL, Meltzer P, Poremba C, Kofler R, Kovar H.

Cancer Res. 2010 May 15;70(10):4015-23. doi: 10.1158/0008-5472.CAN-09-4333.

Items per page

Supplemental Content

Support Center